MDM2 degraders for Merkel cell carcinoma: round peg in a round hole
The study by Ananthapadmanabhan and colleagues examines the efficacy of MDM2 degraders including a clinical stage PROTAC degrader, KMT-253, in models of Merkel cell carcinoma, showing superior efficacy compared with inhibitors.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy
- Repurposed pinworm medication shows ‘promise’ as treatment for Merkel cell carcinoma
- Merkel Cell Carcinoma: Epidemiology, Target, and Therapy
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
- Avelumab in patients with chemotherapy‑refractory metastatic Merkel cell carcinoma: a multicentre, single‑group, open‑label, phase 2 trial